Published in
American Society of Clinical Oncology, Journal of Clinical Oncology, 15_suppl(36), p. 9574-9574
DOI: 10.1200/jco.2018.36.15_suppl.9574
Links
Tools
Mutational and immune gene expression profiling at relapse in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (pbo) in the COMBI-AD trial.
Journal article published in 2018 by
Reinhard Dummer,
Axel Hauschild,
Mario Santinami,
Victoria Atkinson,
Mario Mandalà,
Vanna Chiarion-Sileni 
,
James M. G. Larkin,
Marta Nyakas,
Caroline Dutriaux,
Andrew Mark Haydon,
Caroline Robert,
Dirk Schadendorf,
Paola Aimone,
Bijoyesh Mookerjee,
Catarina D. Campbell
and other authors.
,
James M. G. Larkin,
Marta Nyakas,
Caroline Dutriaux,
Andrew Mark Haydon,
Caroline Robert,
Dirk Schadendorf,
Paola Aimone,
Bijoyesh Mookerjee,
Catarina D. Campbell
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 